Macrolide vs. placebo for mycoplasma pneumonia in children
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether azithromycin (a macrolide antibiotic) is better than a placebo for treating mycoplasma pneumonia in children aged 3–17. If your child has pneumonia caused by mycoplasma, this study may help find the best treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 3 and 17 years old.
- Your child has a clinical diagnosis of community-acquired pneumonia (CAP) with fever and fast breathing.
- Your child tests positive for mycoplasma pneumonia using a rapid test.
- Your child has no history of allergy to azithromycin, heart problems, or other serious lung conditions.
- Your child has not taken antibiotics for mycoplasma in the last 7 days.
- Your child can take oral medication and you can complete follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two antibiotics to find which works better in children with pneumonia caused by a bacteria called mycoplasma that may not respond to usual treatments. It helps choose the most effective treatment for this specific infection.
This trial compares a shorter course of antibiotics to the usual longer course for children hospitalized with uncomplicated bacterial pneumonia. The goal is to see if fewer days of antibiotics work just as well, which could reduce side effects and make treatment easier.
This trial tests whether the antibiotic azithromycin can help children in the hospital who are having asthma-like breathing symptoms. If you qualify, your child may get azithromycin as part of the study and will be monitored closely for side effects and breathing improvement.
This trial tests whether giving a low dose of azithromycin (an antibiotic) can prevent lung infections in young children with structural lung damage or congenital lung/airway malformations. The goal is to reduce infections and keep lungs healthier.
This trial compares different antibiotic strategies for children with pneumonia who are being treated as outpatients. The goal is to find the best approach to treat the infection and help your child recover.
This trial tests whether adding the antibiotic azithromycin to standard asthma treatments helps children with severe asthma in the pediatric intensive care unit (PICU) recover faster. It is for children ages 3 to 17 who are already receiving strong asthma medicines and steroids.
Hear when a new Community Acquired Pneumonia in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.